Glecaprevir / Pibrentasvir

Atorvastatin

Contraindicated.

Available pharmaceutical opinion

Document made available to the pharmacist to communicate a drug interaction to the doctor.

DOWNLOAD
Mechanism

Glecaprevir / Pibrentasvir may inhibit hepatic transports OATP1B1/B3, P-gp and BCRP and increase plasma concentration of Tenofovir Atorvastatin.

Glecaprevir / Pibrentasvir

Pharmacodynamic effects

Recommendations

Alternative solution(s)

Atorvastatin

Pharmacodynamic effects

Possible increased risk of HMG CoA inhibitor toxicity.

Recommendations

Avoid association. Choose an alternative.

Alternative solution(s)

Monitor

Symptoms of toxicity associated with hypolipidemic agents : gastrointestinal effects, fatigue and muscular weaknesses, myalgias, muscular cramps, myopathies, rhabdomyolysis and myoglobinuria leading to renal insufficiency.

Tests

Pharmacokinetic parameters
Parameters
Reference number
# patients
HCV
Dose
Frequency
Cmax
AUC
Glecaprevir / Pibrentasvir
3373
11
-
400/120 mg
QD
 
 
Atorvastatin
3373
11
-
10 mg
QD
+ 2100% (22x)
+ 728% (8.3x)
Comment

Reference
  • 3373
    Glecaprevir/Pibrentasvir (Maviret), Abbvie, Québec, Canada, 19 février 2020.